CN
CNTB.O
—
NASDAQ
Pharmaceuticals & Medical Research
Connect Biopharma Holdings Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
125,9M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
984
Day range
$2,40–$2,56
Prev close
$2,40
Open
$2,41
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Connect Biopharma Holdings Ltd is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
Business. Connect Biopharma Holdings Ltd (CNTB.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY5 analysts
5 buy0 hold0 sell
Avg 12m price target8,38
Analyst recommendations
5 analysts · consensus BuyBuy5
Hold0
Sell0
12-month price target
8,38
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
5 analysts · indicative
Ownership→
Goldman Sachs Asset Management, L.P.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CNTB.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Connect Biopharma Holdings Ltd (CNTB.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDConnect Biopharma has a market capitalization of $156.15 million, with a current market price of $2.48 per share. The company has no dilution risk in the near term, as the number of basic and diluted shares outstanding is identical at 62.96 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the current dataset, and no industry-specific preferred metrics are provided for comparison. Analysts have assigned a mean price target of $8.38 and a median price target of $8.25, indicating a potential upside of over 230% from the current market price.
The company does not disclose segment or geographic revenue breakdowns in the available data, so no conclusions can be drawn about revenue concentration or geographic exposure.
Outlook data is not available in the current dataset, but analyst estimates suggest strong interest in the company’s future performance, with 2 strong-buy and 3 buy ratings.
No recent filings or transcripts are available in the current dataset to inform recent events or strategic developments.
Dilution risk is currently low, as the number of basic and diluted shares is the same, and no dilution adjustments are recorded in the valuation snapshot.
Key takeaways
- Connect Biopharma is a biotechnology company with a market cap of $156.15 million and a current share price of $2.48.
- Analysts have assigned a mean price target of $8.38, suggesting a potential upside of over 230%.
- The company has no immediate dilution risk, as basic and diluted shares are equal.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- No segment or geographic revenue breakdown is available, limiting visibility into revenue concentration.
- Analysts have issued 2 strong-buy and 3 buy ratings, with no hold or sell ratings.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $169.0k; Operating income −71,3% YoY.
Revenue$169.0k
Operating income-$19.6M−71,3 % YoY
Net income—
Free cash flow—
EPS—
Operating cash flow-$16.0M−60,7 % YoY
Financials
Income statement
Revenue$169.0k
Gross profit—
Operating income-$19.6M
Net income—
Margins
Gross margin—
Operating margin-11601.8%
Net margin—
FCF margin—
Balance sheet
Total assets—
Total liabilities$17.4M
Total equity$42.6M
Cash & equivalents$46.0M
Long-term debt—
Cash flow
Operating cash flow-$16.0M
CapEx$0.00
Free cash flow—
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $169.0k
- ▍Operating income −71,3% YoY
- ▍Operating margin -11601.8%
QUARTERLYFiled 2025-11-12
Q3 2025 · Quarter highlights
Revenue $0.00; Operating income -$15.5M.
Revenue$0.00
Operating income-$15.5M
Net income-$15.1M
Free cash flow-$14.9M
EPS—
Operating cash flow-$51.2M
Financials
Income statement
Revenue$0.00
Gross profit—
Operating income-$15.5M
Net income-$15.1M
Balance sheet
Total assets$56.1M
Total liabilities$14.1M
Total equity$42.0M
Cash & equivalents$38.3M
Long-term debt$0.00
Cash flow
Operating cash flow-$51.2M
CapEx-$434.0k
Free cash flow-$14.9M
SBC—
Highlights
- ▍Revenue $0.00
- ▍Operating income -$15.5M
QUARTERLYFiled 2025-08-13
Q2 2025 · Quarter highlights
Revenue $16.0k, −98,7% YoY; Operating income −27,7% YoY.
Revenue$16.0k−98,7 % YoY
Operating income-$17.7M−27,7 % YoY
Net income-$17.2M−33,6 % YoY
Free cash flow-$17.1M−34,3 % YoY
EPS—
Operating cash flow-$40.0M−87,7 % YoY
Financials
Income statement
Revenue$16.0k
Gross profit—
Operating income-$17.7M
Net income-$17.2M
Margins
Gross margin—
Operating margin-110481.2%
Net margin-107500.0%
FCF margin-106593.8%
Balance sheet
Total assets$67.4M
Total liabilities$12.0M
Total equity$55.4M
Cash & equivalents$37.8M
Long-term debt$0.00
Cash flow
Operating cash flow-$40.0M
CapEx-$418.0k
Free cash flow-$17.1M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $16.0k, −98,7% YoY
- ▍Operating income −27,7% YoY
- ▍Net income −33,6% YoY
- ▍Free cash flow −34,3% YoY
- ▍Net margin -107500.0%
QUARTERLYFiled 2025-05-15
Q1 2025 · Quarter highlights
Revenue $48.0k; Operating income -$13.4M.
Revenue$48.0k
Operating income-$13.4M
Net income-$12.9M
Free cash flow-$13.0M
EPS—
Operating cash flow-$22.6M
Financials
Income statement
Revenue$48.0k
Gross profit—
Operating income-$13.4M
Net income-$12.9M
Margins
Gross margin—
Operating margin-27966.7%
Net margin-26872.9%
FCF margin-27147.9%
Balance sheet
Total assets$82.7M
Total liabilities$11.4M
Total equity$71.3M
Cash & equivalents$40.6M
Long-term debt$0.00
Cash flow
Operating cash flow-$22.6M
CapEx-$384.0k
Free cash flow-$13.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $48.0k
- ▍Operating income -$13.4M
- ▍Net margin -26872.9%
ANNUALFiled 2026-03-31
FY 2026 · Full-year highlights
Revenue $64.0k, −99,8% YoY; Operating income −158,7% YoY.
Revenue$64.0k−99,8 % YoY
Operating income-$58.1M−158,7 % YoY
Net income-$55.5M−255,0 % YoY
Free cash flow-$55.2M−252,2 % YoY
EPS—
Operating cash flow-$51.2M−116,9 % YoY
Financials
Income statement
Revenue$64.0k
Gross profit—
Operating income-$58.1M
Net income-$55.5M
Margins
Gross margin—
Operating margin-90740.6%
Net margin-86687.5%
FCF margin-86265.6%
Balance sheet
Total assets$56.1M
Total liabilities$14.1M
Total equity$42.0M
Cash & equivalents$38.3M
Long-term debt$0.00
Cash flow
Operating cash flow-$51.2M
CapEx-$434.0k
Free cash flow-$55.2M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $64.0k, −99,8% YoY
- ▍Operating income −158,7% YoY
- ▍Net income −255,0% YoY
- ▍Free cash flow −252,2% YoY
- ▍Net margin -86687.5%
ANNUALFiled 2025-03-31
FY 2025 · Full-year highlights
Revenue $26.0M; Operating income +67,5% YoY.
Revenue$26.0M
Operating income-$22.5M+67,5 % YoY
Net income-$15.6M+74,8 % YoY
Free cash flow-$15.7M+74,5 % YoY
EPS—
Operating cash flow-$23.6M+50,5 % YoY
Financials
Income statement
Revenue$26.0M
Gross profit—
Operating income-$22.5M
Net income-$15.6M
Margins
Gross margin—
Operating margin-86.2%
Net margin-60.0%
FCF margin-60.2%
Balance sheet
Total assets$101.3M
Total liabilities$9.1M
Total equity$92.2M
Cash & equivalents$78.2M
Long-term debt$0.00
Cash flow
Operating cash flow-$23.6M
CapEx-$750.0k
Free cash flow-$15.7M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $26.0M
- ▍Operating income +67,5% YoY
- ▍Net income +74,8% YoY
- ▍Free cash flow +74,5% YoY
- ▍Net margin -60.0%
ANNUALFiled 2024-04-16
FY 2024 · Full-year highlights
Revenue $0.00; Operating income +42,1% YoY.
Revenue$0.00
Operating income-$69.1M+42,1 % YoY
Net income-$62.1M+47,4 % YoY
Free cash flow-$61.5M+49,4 % YoY
EPS—
Operating cash flow-$47.7M+53,0 % YoY
Financials
Income statement
Revenue$0.00
Gross profit—
Operating income-$69.1M
Net income-$62.1M
Balance sheet
Total assets$127.4M
Total liabilities$25.9M
Total equity$101.5M
Cash & equivalents$105.7M
Long-term debt$0.00
Cash flow
Operating cash flow-$47.7M
CapEx-$81.0k
Free cash flow-$61.5M
SBC—
Highlights
- ▍Revenue $0.00
- ▍Operating income +42,1% YoY
- ▍Net income +47,4% YoY
- ▍Free cash flow +49,4% YoY
ANNUALFiled 2023-04-11
FY 2023 · Full-year highlights
Operating income −21,6% YoY; Net income +41,6% YoY.
Revenue—
Operating income-$119.3M−21,6 % YoY
Net income-$118.1M+41,6 % YoY
Free cash flow-$121.5M+40,9 % YoY
EPS—
Operating cash flow-$101.5M−20,4 % YoY
Financials
Income statement
Revenue—
Gross profit—
Operating income-$119.3M
Net income-$118.1M
Balance sheet
Total assets$174.0M
Total liabilities$16.5M
Total equity$157.5M
Cash & equivalents$28.3M
Long-term debt$431.0k
Cash flow
Operating cash flow-$101.5M
CapEx-$4.4M
Free cash flow-$121.5M
SBC—
Highlights
- ▍Operating income −21,6% YoY
- ▍Net income +41,6% YoY
- ▍Free cash flow +40,9% YoY
ANNUALFiled 2022-03-31
FY 2022 · Full-year highlights
Operating income -$98.1M.
Revenue—
Operating income-$98.1M
Net income-$202.3M
Free cash flow-$205.5M
EPS—
Operating cash flow-$84.3M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$98.1M
Net income-$202.3M
Balance sheet
Total assets$291.1M
Total liabilities$18.8M
Total equity$272.3M
Cash & equivalents$267.7M
Long-term debt$125.0k
Cash flow
Operating cash flow-$84.3M
CapEx-$3.9M
Free cash flow-$205.5M
SBC—
Highlights
- ▍Operating income -$98.1M
Valuation FY
Market price
$2,00
Market cap
$156.2M
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships6 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries6
EX21:099f25a958b5EX21:099f25a958b5Subsidiarie97%
EX21:628e2522492aEX21:628e2522492aSubsidiarie97%
EX21:62c067a41610EX21:62c067a41610Subsidiarie97%
EX21:ce343427e152EX21:ce343427e152Subsidiarie97%
EX21:f782314e4ae6EX21:f782314e4ae6Subsidiarie97%
EX21:f8551befdb49EX21:f8551befdb49Subsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs CNTB · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
— vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
— vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
— vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
— vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
— vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
— vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-3,96
Predicted surprise
+0,00
Beat probability
45 %
Analysts
5
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,96 |
| Revenue | —no estimate | —no estimate | 5,0M USD |
| Operating income | —no estimate | —no estimate | -265,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution5 analysts
Strong buy2
Buy3
Hold0
Sell0
Strong sell0
12-month price target$8,38 · Median $8,25
Low $7,00High $10,00
Operating income · consensus-265,6M USD
EPS surprise
−81,5 %
reported vs consensus · miss
Revenue surprise
−90,8 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$7,00
Mean$8,38
Median$8,25
High$10,00
Spot$2,00
+318.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Connect Biopharma Holdings Ltd Market data — financials · 2026-05-27
- Connect Biopharma Holdings Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net buying2 buys · 0 sellsnet $4,4M3 insiders · last 365d
- Director · Ordinary SharesBought 150 000 @ $2,48$372K · 2026-05-29
- Director · Ordinary SharesOther 2 816 · 2026-03-31
- Director · Ordinary SharesBought 1 160 000 @ $3,45$4,0M · 2026-03-31
- Director · Ordinary SharesOther 5 061 · 2026-03-31
Short positioning
2.1Mshares short+55.3% vs prior
2.78days to cover
27.8%short of daily vol
2.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CNTB.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): -255.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -116.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -158.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 54.6%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 29.2%Derived (calculated)
- Net margin (FY 2025-12-31): -86,687.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -132.2%Derived (calculated)
- Return on assets (FY 2025-12-31): -98.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.74xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.34xDerived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -99.8%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -42.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -51.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -44.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -54.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -257.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -257.1%Derived (calculated)
- R&D expense (annual): USD 37.8MSEC XBRL filing
- Operating income (annual): USD -58.07MSEC XBRL filing
- Current liabilities (annual): USD 13.61MSEC XBRL filing
- Current assets (annual): USD 50.93MSEC XBRL filing
- Shares outstanding (annual): 56.44MSEC XBRL filing
- Operating cash flow (annual): USD -51.21MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 00:00 UTCINSIDER1 insider transaction — 2026-05 · net buy $372k
2026-05-29INSIDERHuang James bought 150.0k sh Ordinary Shares — Director ~$372k
2026-03-31 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.2M
2026-03-31 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 0.1M · Net USD -55.5M
2026-03-31 00:00 UTCINSIDER3 insider transactions — 2026-03 · net buy $4.0M
2026-03-31INSIDERXanthopoulos Kleanthis Gabriel transacted 2.8k sh Ordinary Shares — Director
2026-03-31INSIDERHuang James bought 1.16M sh Ordinary Shares — Director ~$4.00M
2026-03-31INSIDERLIU JEAN I transacted 5.1k sh Ordinary Shares — Director
2025-11-12 09:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 0.0M · Net USD -15.1M
2025-08-13 09:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.0M · Net USD -17.2M
2025-05-15 09:03 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 0.0M · Net USD -12.9M
2025-03-31 09:06 UTCEARNINGSAnnual results — FY 2025 Revenue USD 26.0M · Net USD -15.6M
2024-04-16 16:33 UTCEARNINGSAnnual results — FY 2024 Revenue USD 0.0M · Net USD -62.1M
2023-04-11 17:00 UTCEARNINGSAnnual results — FY 2023 Net USD -118.1M
2022-03-31 16:54 UTCEARNINGSAnnual results — FY 2022 Net USD -202.3M
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage